Market Cap 659.89M
Revenue (ttm) 0.00
Net Income (ttm) -183.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 985,400
Avg Vol 1,349,250
Day's Range N/A - N/A
Shares Out 49.95M
Stochastic %K 7%
Beta 0.05
Analysts Strong Sell
Price Target $30.89

Company Profile

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formu...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 999 0075
Fax: 866 553 3269
Address:
55 Cambridge Parkway, Suite 901 East, Cambridge, United States
BiotechBonesaw
BiotechBonesaw Aug. 4 at 10:15 PM
$TNXP we’re in the endgame now. FDA approval could come at any point - $NUVB came 12 days early (6/11 vs 6/23) and that is for a cancer drug that has other recent competitors with similar ROS1+ NSCLC labels. Other approvals have come early; and unfortunately some have been delayed like $KALV and $GSK experienced. There is a decent probability of a delay if RFKJ and his minions keep screwing things up at the FDA. This is an exciting time for Tonix bulls. A lot of bears are still shorting shares. Time to give them the old squeeze 🚀
0 · Reply
Carlito84
Carlito84 Aug. 4 at 4:52 PM
$KALV added more
0 · Reply
G101SPM
G101SPM Jul. 30 at 5:09 PM
$KALV $14.20 bid * DAC (dollar average cost includes partial SELLS at a profit to reduce net cost to $0.89. EXIT $21.00. UPDATE: Co announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., which licensed commercialization rights in Japan to Kaken Pharmaceutical for sebetralstat, received an upfront payment of $11 million, with an additional payment of up to $11 million upon achievement of a regulatory milestone anticipated in early 2026. Beyond these payments, the Company is also eligible for commercial milestone payments, plus royalties based on the Japan National Health Insurance (NHI) price, with the royalty rate as a percentage of sales approximately in the mid-twenties.
1 · Reply
HighBetaBelle
HighBetaBelle Jul. 30 at 2:15 PM
Thought I missed the boat on $TNXP but the dip has allowed me to open a position ahead of PDUFA date. Did the exact same with $KALV on its big dip before their PDUFA
1 · Reply
Carlito84
Carlito84 Jul. 30 at 11:37 AM
$KALV bought more
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 30 at 7:50 AM
$IXHL not only that… we made the NYT! I’m a big man and former college football player… sleep apnea sucks, CPAP machines are terrible for most, and this pill could change & save lives. Wow I wish I has researched this and bought a shit ton of shares when it was 20 cents & @Hoppanin & @squiggleburp gave me a heads up on the $TNXP boards. This is quickly becoming one of my favorite biotechs. Buying more on every dip just like TNXP, $NUVB , $KALV , and $IMRX 🚀 https://m.slashdot.org/story/444966
1 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 29 at 6:55 PM
$TNXP I’m 95% certain that today’s selloff is due to MRK & NVO having terrible updates, dragging most of biopharma down with them. When actually the price should be increasing, particularly given MRK will be more desperate and make more deals a la $VRNA . Biotechs like Tonix & $NUVB & $KALV with clear blockbuster potential should become more valuable given bigger pharma is getting desperate. Good luck to all Biotech Bulls! These diamond hands won’t get scared easily 💎 👊
3 · Reply
Stocker1988
Stocker1988 Jul. 29 at 3:35 PM
$KALV I'm confuse, when do they PR the next ER? is it August, or September?
1 · Reply
edelhead
edelhead Jul. 29 at 12:04 PM
$KALV "Shorts" automatically go after companies soon after FDA approval, mainly because most of those companies stumble of the commercialization gate. BUT the "shorts" have it wrong on Kalvista. Our product is a no-brainer - anyone and everyone who is afflicted with this disease will want to have our pills on their person at all times (instead of a syringe); the pills work just as well as the syringes and the safety is assured. Also, the sales team has been in place for months and the manufacturing is under KALV's control. And wordwide distribution is coming quickly, starting with EU and UK; Japan then follows. This can't miss. This won't miss. "Shorts" will be hurt badly, and soon. The squeeze will come!
1 · Reply
AdiDasRom
AdiDasRom Jul. 29 at 6:57 AM
0 · Reply
Latest News on KALV
US FDA approves KalVista Pharma's swelling disorder drug

Jul 7, 2025, 6:37 AM EDT - 4 weeks ago

US FDA approves KalVista Pharma's swelling disorder drug


KalVista: Poised For Rare Disease Transformation

Apr 12, 2025, 12:42 AM EDT - 4 months ago

KalVista: Poised For Rare Disease Transformation


KalVista Appoints Jeb Ledell as Chief Operating Officer

Dec 16, 2024, 7:00 AM EST - 8 months ago

KalVista Appoints Jeb Ledell as Chief Operating Officer


KalVista Appoints Brian Piekos as Chief Financial Officer

Sep 10, 2024, 6:30 AM EDT - 11 months ago

KalVista Appoints Brian Piekos as Chief Financial Officer


BiotechBonesaw
BiotechBonesaw Aug. 4 at 10:15 PM
$TNXP we’re in the endgame now. FDA approval could come at any point - $NUVB came 12 days early (6/11 vs 6/23) and that is for a cancer drug that has other recent competitors with similar ROS1+ NSCLC labels. Other approvals have come early; and unfortunately some have been delayed like $KALV and $GSK experienced. There is a decent probability of a delay if RFKJ and his minions keep screwing things up at the FDA. This is an exciting time for Tonix bulls. A lot of bears are still shorting shares. Time to give them the old squeeze 🚀
0 · Reply
Carlito84
Carlito84 Aug. 4 at 4:52 PM
$KALV added more
0 · Reply
G101SPM
G101SPM Jul. 30 at 5:09 PM
$KALV $14.20 bid * DAC (dollar average cost includes partial SELLS at a profit to reduce net cost to $0.89. EXIT $21.00. UPDATE: Co announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., which licensed commercialization rights in Japan to Kaken Pharmaceutical for sebetralstat, received an upfront payment of $11 million, with an additional payment of up to $11 million upon achievement of a regulatory milestone anticipated in early 2026. Beyond these payments, the Company is also eligible for commercial milestone payments, plus royalties based on the Japan National Health Insurance (NHI) price, with the royalty rate as a percentage of sales approximately in the mid-twenties.
1 · Reply
HighBetaBelle
HighBetaBelle Jul. 30 at 2:15 PM
Thought I missed the boat on $TNXP but the dip has allowed me to open a position ahead of PDUFA date. Did the exact same with $KALV on its big dip before their PDUFA
1 · Reply
Carlito84
Carlito84 Jul. 30 at 11:37 AM
$KALV bought more
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 30 at 7:50 AM
$IXHL not only that… we made the NYT! I’m a big man and former college football player… sleep apnea sucks, CPAP machines are terrible for most, and this pill could change & save lives. Wow I wish I has researched this and bought a shit ton of shares when it was 20 cents & @Hoppanin & @squiggleburp gave me a heads up on the $TNXP boards. This is quickly becoming one of my favorite biotechs. Buying more on every dip just like TNXP, $NUVB , $KALV , and $IMRX 🚀 https://m.slashdot.org/story/444966
1 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 29 at 6:55 PM
$TNXP I’m 95% certain that today’s selloff is due to MRK & NVO having terrible updates, dragging most of biopharma down with them. When actually the price should be increasing, particularly given MRK will be more desperate and make more deals a la $VRNA . Biotechs like Tonix & $NUVB & $KALV with clear blockbuster potential should become more valuable given bigger pharma is getting desperate. Good luck to all Biotech Bulls! These diamond hands won’t get scared easily 💎 👊
3 · Reply
Stocker1988
Stocker1988 Jul. 29 at 3:35 PM
$KALV I'm confuse, when do they PR the next ER? is it August, or September?
1 · Reply
edelhead
edelhead Jul. 29 at 12:04 PM
$KALV "Shorts" automatically go after companies soon after FDA approval, mainly because most of those companies stumble of the commercialization gate. BUT the "shorts" have it wrong on Kalvista. Our product is a no-brainer - anyone and everyone who is afflicted with this disease will want to have our pills on their person at all times (instead of a syringe); the pills work just as well as the syringes and the safety is assured. Also, the sales team has been in place for months and the manufacturing is under KALV's control. And wordwide distribution is coming quickly, starting with EU and UK; Japan then follows. This can't miss. This won't miss. "Shorts" will be hurt badly, and soon. The squeeze will come!
1 · Reply
AdiDasRom
AdiDasRom Jul. 29 at 6:57 AM
0 · Reply
HamBoneXoXo
HamBoneXoXo Jul. 29 at 6:48 AM
$KALV I am surprised folks are puzzled by the pps drops. Until they show drug uptake and project a rev stream, it won’t go far than sideways with a downward bias.
1 · Reply
AdiDasRom
AdiDasRom Jul. 29 at 5:46 AM
$KALV KalVista Pharmaceuticals (KALV) received positive opinion from the European Medicines Agency
0 · Reply
PokerMunkee
PokerMunkee Jul. 28 at 9:58 PM
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 28 at 9:35 PM
$KALV tariffs are a potential reason. Pharma’s not exempt from them and this is a European biotech 🤷‍♂️ Buying dips.
1 · Reply
cghaynes0182
cghaynes0182 Jul. 28 at 6:35 PM
$KALV anyone have any thoughts of why this is dropped 10% in the last week?
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 28 at 6:33 PM
$TNXP most of biotech is selling off today. Not clear if it’s because of Trump’s uncertainty whether pharma is covered by the 15% tariff deal with the EU (he said it wasn’t but it likely is). Or if it’s just profit taking amidst typical FUD biotech fear. Or if the FDA is falling further behind due to RFKJ/DOGE’s cuts (this is probably the most likely given $KALV and others’ PDUFAs were delayed) If it keeps dropping I’ll buy more. Can’t wait to see what happens in August 📆 A diamond fist is not enough! Tonix must be DIAMOND FACED! 💎 GLB 👍 ☘️ 🐂
1 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 28 at 2:53 AM
Here are my Fantastic Five of Biotech. Agree or disagree if you want, but I think all have 3x bagger potential… and a couple have 10-20x in the next couple of years. 1) $TNXP - my top holding in biotech and overall now thanks to its rapid growth and my aggressive buying. Tonmya will help millions of fibromyalgia patients avoid pain & sleep better. I only wish I had bought more as @Hoppanin , @Proposition_Joe , @PeteyUSA , and every other Tonix Pioneer knows 😩 2) $NUVB - hot oncology company with a recent ROS1+ NSCLC approval and a growing pipeline highlighted by a potential BIC IDH inhibitor (brain cancer / others). Their CEO sold Medivation to PFE for $14B & it was probably Pfizer’s best deal this century - aside from the COVID vaccines. 3) $KALV - recent oral HAE approval- can’t wait to see sales (rare disease, likely BO) 4) $IMRX - potential frontline pancreatic cancer gamechanger 5) $IXHL - cheap sleep apnea biotech. Major upside - I’m buying dips. GLB 🐂 More 2 come
4 · Reply
Trustfundkid69
Trustfundkid69 Jul. 25 at 6:14 PM
$KALV anything to do with European label? But seemed exactly what it should be?
2 · Reply
Trustfundkid69
Trustfundkid69 Jul. 25 at 1:40 PM
$KALV haha such weird price action this morning, regardless I’m in for the long haul, but interesting to see
0 · Reply
G101SPM
G101SPM Jul. 25 at 12:25 PM
$KALV $15.89 bid. *DAC (dollar average cost includes partial SELLS at profit to reduce cost to $0.89). EXIT $21.00. UPDATE: KalVista Pharmaceuticals receives positive CHMP opinion for sebetralstat for the treatment of hereditary angioedema attacks note: If approved, sebetralstat will be the first and only oral on-demand treatment for HAE in the European Union. European Commission decision expected by early October 2025. * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
0 · Reply
Shakattack31
Shakattack31 Jul. 25 at 12:19 PM
$KALV where's the 🚀?
0 · Reply
TwongStocks
TwongStocks Jul. 25 at 12:08 PM
$KALV Company PR on the positive CHMP opinion https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-receives-positive-chmp-opinion "The European Commission (EC) final decision is expected by early October." EC decision is usually within 67 days of the positive CHMP opinion.
0 · Reply